Received: 30 January 2023
Accepted: 9 August 2023
First Online: 24 August 2023
: The authors confirm that the approval of an institutional review board was not required for this work. Informed consent was obtained. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.
: Patient written informed consent was obtained for this case report.
: The authors report no disclosures relevant to the manuscript. Dr. AbdelRazek received consulting fees from Bristol-Myers Squibb and Horizon Therapeutics in 2022.